Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Neurology and TherapyOpen Access

Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKayoko SaitoTSToshio SaitoRAReiko Arakawa

Discussion

Loading...

Member takes

Overview

Postmarketing surveillance study assesses safety of risdiplam in Japanese SMA patients, suggesting favorable outcomes.

Key Points

  • Risdiplam showed good safety and tolerability in Japanese patients with spinal muscular atrophy.
  • Adverse drug reactions were reported in 20.8% of patients, with gastrointestinal disorders being the most common.
  • The study involved 538 patients from 259 institutions in Japan, assessed over 12 months.
  • Significant findings include a higher incidence of gastrointestinal issues linked to older age and comorbidities.

Cite This Study

Saito et al. (2025) studied this question.

synapsesocial.com/papers/68c24236b210217d647a2eabhttps://doi.org/10.1007/s40120-025-00795-x
View Full Paper
Ask AI
Bookmark
Share